Crossref
Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia
American Journal of Blood Research · 2026 · 16 (4) · 65-72
DOI: 10.62347/mayh4508 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Blood Research, 2026. Verfasst von Nader Shakibazad und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Shakibazad, N., Anbaraki, F., & Marzban, M. (2026). Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia. American Journal of Blood Research, 16(4), 65-72. https://doi.org/10.62347/mayh4508
Vancouver
Shakibazad N, Anbaraki F, Marzban M. Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia. American Journal of Blood Research. 2026;16(4):65-72. doi:10.62347/mayh4508
BibTeX
@article{Shakibazad2026,
author = {Shakibazad, Nader and Anbaraki, Fatemeh and Marzban, Maryam},
title = {Fetal-to-sickle hemoglobin index and clinical morbidity in hydroxyurea-treated sickle cell anemia},
journal = {American Journal of Blood Research},
year = {2026},
volume = {16},
number = {4},
pages = {65--72},
doi = {10.62347/mayh4508}
}
EUVIMED